Loading clinical trials...
Loading clinical trials...
The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AstraZeneca
Collaborators
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT06278207 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
NCT06887049 · Type 2 Diabetes Mellitus (T2DM), Diabetes Distress
NCT07433062 · Type 2 Diabetes Mellitus
The Children Hospital Of Alabama
Birmingham, Alabama
Axis Clinical Trials
Los Angeles, California
Nemours Childrens Hospital
Orlando, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions